

## ***Illicit Trade***

### **Trade in Counterfeit Pharmaceutical Products**

DOI: <https://doi.org/10.1787/26175835>

ISBN 978-92-64-76946-5 (print)

ISBN 978-92-64-60697-5 (PDF)

© OECD 2020

## **Corrigendum**

**Page 5:** we added a name, Peter Avery.

**Page 58:** instead of "Merck addresses the challenges associated with counterfeiting in its annual report (Merck & Co., Inc, 2019a):", we wrote "Merck addresses the challenges associated with counterfeiting in its annual report (**Merck KGaA, 2019**):"

**Page 58:** "Although counterfeiting is not mentioned in its annual financial report it does however document certain trademark infringement litigation (Merck & Co., Inc, 2019b)." It was changed to "Although counterfeiting is not mentioned in **the MSD** annual financial report it does however document certain trademark infringement litigation (Merck & Co., Inc, 2019)."

**Page 66:** "Merck & Co., Inc. (2019a), Science: Annual report 2018, Merck & Co., Inc., Kenilworth, [www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2018-q4/en/2018-Q4-Report-EN.pdf](http://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2018-q4/en/2018-Q4-Report-EN.pdf)." was changed to "**Merck KGaA (2019)**, Science: **Annual report 2018, Merck KGaA, Darmstadt, Germany**, [www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2018-q4/en/2018-Q4-Report-EN.pdf](http://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2018-q4/en/2018-Q4-Report-EN.pdf)."